ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Scope & Guideline

Pioneering Innovations in Infectious Disease Research

Introduction

Welcome to the ANTIMICROBIAL AGENTS AND CHEMOTHERAPY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0066-4804
PublisherAMER SOC MICROBIOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1963 to 1970, from 1972 to 2024
AbbreviationANTIMICROB AGENTS CH / Antimicrob. Agents Chemother.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1752 N ST NW, WASHINGTON, DC 20036-2904

Aims and Scopes

The journal 'Antimicrobial Agents and Chemotherapy' focuses on advancing the understanding of antimicrobial agents and their applications in treating infectious diseases. It emphasizes research that spans the microbiological, pharmacological, and clinical dimensions, providing a platform for innovative studies that address contemporary challenges in antimicrobial therapy.
  1. Antimicrobial Resistance Mechanisms:
    Research on the mechanisms by which bacteria and fungi develop resistance to various antimicrobial agents, including β-lactams, fluoroquinolones, and antifungals.
  2. Clinical Pharmacokinetics and Pharmacodynamics:
    Studies that analyze the pharmacokinetics and pharmacodynamics of antimicrobial agents, aiming to optimize dosing regimens and improve therapeutic outcomes.
  3. Novel Antimicrobial Agents:
    Development and evaluation of new antimicrobial compounds, including novel antibiotics, antivirals, and antifungals, targeting resistant pathogens.
  4. In Vitro and In Vivo Efficacy Studies:
    Evaluation of antimicrobial efficacy through laboratory and clinical studies, including animal models, to assess the effectiveness of new and existing therapies.
  5. Epidemiological Surveillance:
    Investigations into the epidemiology of infectious diseases, including the prevalence and spread of resistant strains in various populations.
  6. Innovative Therapeutic Approaches:
    Research on combination therapies, phage therapy, and other novel strategies to enhance the efficacy of existing antimicrobial treatments.
Recent publications reflect dynamic shifts in the research landscape of antimicrobial agents, highlighting emerging themes that are gaining increased attention. These trends indicate the evolving nature of infectious disease challenges and the response of the scientific community.
  1. Antimicrobial Stewardship:
    Growing focus on antimicrobial stewardship programs aimed at optimizing the use of antimicrobials to combat resistance and improve patient outcomes.
  2. Phage Therapy:
    Increased interest in bacteriophage therapy as a viable alternative or adjunct to antibiotics, particularly against multidrug-resistant bacteria.
  3. Machine Learning and AI in Drug Development:
    Application of machine learning and artificial intelligence techniques to predict antimicrobial efficacy, optimize dosing regimens, and identify novel drug candidates.
  4. Global Surveillance of Resistance Patterns:
    Enhanced efforts in global surveillance studies to track antimicrobial resistance patterns, particularly in response to the COVID-19 pandemic.
  5. Pharmacogenomics:
    Emerging research into pharmacogenomic factors affecting antimicrobial therapy, tailoring treatments based on individual genetic profiles.
  6. Combination Therapy Approaches:
    A trend towards exploring combination therapies that synergize multiple agents to enhance efficacy against resistant pathogens.

Declining or Waning

While the journal continues to cover a wide range of topics in antimicrobial research, certain areas have seen a decline in publication frequency or interest. This may indicate shifting research priorities or the saturation of previously hot topics.
  1. Traditional Antibiotics:
    Research focusing on the efficacy of traditional antibiotics has diminished as the field shifts towards exploring novel agents and combination therapies.
  2. Single-Agent Studies:
    There has been a noticeable reduction in studies investigating the effectiveness of single-agent treatments, as the focus moves towards combination therapies to combat resistance.
  3. Non-Pharmacological Interventions:
    Studies examining non-pharmacological interventions (e.g., infection control measures) in antimicrobial therapy have decreased, likely due to a greater emphasis on drug development.
  4. Antifungal Resistance Mechanisms:
    While antifungal resistance remains a concern, the volume of research specifically addressing resistance mechanisms has seen a relative decline compared to the surge in studies on bacterial resistance.

Similar Journals

Reviews and Research in Medical Microbiology

Your Essential Resource for Medical Microbiology Advancements
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2770-3150Frequency: 4 issues/year

Reviews and Research in Medical Microbiology is a premier academic journal published by LIPPINCOTT WILLIAMS & WILKINS, focusing on groundbreaking research and comprehensive reviews that advance the understanding of medical microbiology. With an ISSN of 2770-3150 and an E-ISSN of 2770-3169, this journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of pathogens, infectious diseases, and microbial mechanisms affecting health. While the journal currently does not offer open access, its rigorous peer-review process ensures that only high-quality, impactful research is disseminated to the scientific community. The journal aims to bridge gaps in knowledge by presenting cutting-edge studies that explore novel therapeutic strategies, diagnostic methods, and the evolving landscape of microbial resistance. Nestled in the heart of Philadelphia, this journal proudly contributes to the advancement of medical microbiology and is an indispensable platform for the publication of critical findings that shape clinical practices and research trajectories in the field.

Asian Pacific Journal of Tropical Biomedicine

Empowering Researchers with Open Access Knowledge.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2221-1691Frequency: 12 issues/year

The Asian Pacific Journal of Tropical Biomedicine, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing research in the fields of tropical biomedicine. Launched in 2011 and fully embracing the open-access model since 2014, this journal has become an invaluable resource for researchers, professionals, and students alike. With an impact factor reflective of its Q3 ranking in the category of Biochemistry, Genetics and Molecular Biology (miscellaneous), it currently holds a Scopus rank of #49 out of 103, placing it in the 52nd percentile in its field. Covering diverse topics on biomedicine, the journal aims to disseminate significant findings and foster collaborative research initiatives across the Asian Pacific region and beyond. With its robust commitment to accessibility and quality, the Asian Pacific Journal of Tropical Biomedicine is a vital platform for promoting scientific knowledge and innovation.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Exploring Therapeutic Breakthroughs for Better Animal Welfare
Publisher: WILEYISSN: 0140-7783Frequency: 6 issues/year

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.

Drug Discoveries and Therapeutics

Empowering researchers with cutting-edge insights.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Infectious Diseases and Therapy

Empowering discovery in infectious disease therapy.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Journal of Global Antimicrobial Resistance

Empowering research to combat resistance worldwide.
Publisher: ELSEVIER SCI LTDISSN: 2213-7165Frequency: 4 issues/year

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

JAC-Antimicrobial Resistance

Bridging Knowledge Gaps in Antimicrobial Resistance
Publisher: OXFORD UNIV PRESSISSN: Frequency: 4 issues/year

JAC-Antimicrobial Resistance, published by Oxford University Press, is a pioneering open-access journal that has been contributing to the vital discourse on antimicrobial resistance since its inception in 2019. With an E-ISSN of 2632-1823, the journal operates out of the United Kingdom and is dedicated to advancing our understanding of antimicrobial resistance mechanisms, impacts, and solutions across a variety of related fields including Immunology, Infectious Diseases, and Microbiology. The journal currently ranks in the Q2 category for these disciplines, highlighting its growing impact and relevance within the academic community. Researchers, practitioners, and students alike will find a treasure trove of high-quality, peer-reviewed articles that are freely accessible, aligning with contemporary trends in scientific publishing. As the world grapples with the rising threat of antimicrobial resistance, JAC-Antimicrobial Resistance stands as an essential resource for those seeking to stay at the forefront of this critical field.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Advancing cancer treatment through innovative pharmacology.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Fostering Collaboration in Life Sciences Research
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

JOURNAL OF CHEMOTHERAPY

Pioneering Knowledge in Chemotherapy and Beyond
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.